Neuronal prostaglandin E2 receptor subtype EP3 mediates antinociception during inflammation

Area of Science:

• Neuroscience
• Pharmacology
• Pain Research

Background:

• Prostaglandin E2 (PGE2) is a key pain mediator that sensitizes nociceptive pathways via EP2 and EP4 receptors.
• PGE2 also activates EP3 receptors, which are coupled to Gi proteins and inhibit cAMP, presenting a potential counteracting mechanism to pain sensitization.

Purpose of the Study:

• To investigate the role of the Gi-protein-coupled EP3 receptor in counteracting PGE2-mediated pronociceptive effects.
• To explore the potential of selective EP3 receptor activation as a therapeutic strategy for inflammatory pain.

Main Methods:

• Examined EP3 receptor localization in primary sensory neurons and the spinal cord.
• Assessed the effects of selective EP3 receptor activation on nociceptive neurons in healthy and inflamed conditions.
• Investigated EP3 receptor interactions with other EP receptors in isolated dorsal root ganglion neurons.

Main Results:

• EP3 receptors are extensively localized in primary sensory neurons and the spinal cord.
• Selective EP3 receptor activation did not sensitize neurons in healthy animals but produced analgesia in inflamed joints.
• EP3 receptor activation counteracted PGE2-induced sensitization in isolated neurons, with excitatory EP receptor stimulation promoting inhibitory EP3 receptor expression.

Conclusions:

• The EP3 receptor plays a role in endogenous pain control, particularly in inflammatory pain.
• Selective EP3 receptor activation represents a novel therapeutic approach to reverse inflammatory pain.
• EP3 receptors are present in the joint nerves of osteoarthritis patients, highlighting their clinical relevance.